Literature DB >> 22150623

Cannabinoid hyperemesis syndrome.

Jonathan A Galli1, Ronald Andari Sawaya, Frank K Friedenberg.   

Abstract

Coinciding with the increasing rates of cannabis abuse has been the recognition of a new clinical condition known as Cannabinoid Hyperemesis Syndrome. Cannabinoid Hyperemesis Syndrome is characterized by chronic cannabis use, cyclic episodes of nausea and vomiting, and frequent hot bathing. Cannabinoid Hyperemesis Syndrome occurs by an unknown mechanism. Despite the well-established anti-emetic properties of marijuana, there is increasing evidence of its paradoxical effects on the gastrointestinal tract and CNS. Tetrahydrocannabinol, cannabidiol, and cannabigerol are three cannabinoids found in the cannabis plant with opposing effects on the emesis response. The clinical course of Cannabinoid Hyperemesis Syndrome may be divided into three phases: prodromal, hyperemetic, and recovery phase. The hyperemetic phase usually ceases within 48 hours, and treatment involves supportive therapy with fluid resuscitation and anti-emetic medications. Patients often demonstrate the learned behavior of frequent hot bathing, which produces temporary cessation of nausea, vomiting, and abdominal pain. The broad differential diagnosis of nausea and vomiting often leads to delay in the diagnosis of Cannabinoid Hyperemesis Syndrome. Cyclic Vomiting Syndrome shares several similarities with CHS and the two conditions are often confused. Knowledge of the epidemiology, pathophysiology, and natural course of Cannabinoid Hyperemesis Syndrome is limited and requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22150623      PMCID: PMC3576702          DOI: 10.2174/1874473711104040241

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  72 in total

1.  Inhibitory effect of cannabinoid agonists on gastric emptying in the rat.

Authors:  A A Izzo; N Mascolo; R Capasso; M P Germanò; R De Pasquale; F Capasso
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-08       Impact factor: 3.000

Review 2.  AGA technical review on nausea and vomiting.

Authors:  E M Quigley; W L Hasler; H P Parkman
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

Review 3.  The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential.

Authors:  S H Burstein
Journal:  Pharmacol Ther       Date:  1999-04       Impact factor: 12.310

Review 4.  Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report.

Authors:  S J Watson; J A Benson; J E Joy
Journal:  Arch Gen Psychiatry       Date:  2000-06

Review 5.  Cannabinoids and the gastrointestinal tract.

Authors:  R G Pertwee
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

6.  The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.

Authors:  Nissar A Darmani
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

Review 7.  Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.

Authors:  A Giuffrida; M Beltramo; D Piomelli
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

8.  Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors.

Authors:  Z K Krowicki; J M Moerschbaecher; P J Winsauer; S V Digavalli; P J Hornby
Journal:  Eur J Pharmacol       Date:  1999-04-29       Impact factor: 4.432

Review 9.  Pharmacology of cannabinoid receptor ligands.

Authors:  R G Pertwee
Journal:  Curr Med Chem       Date:  1999-08       Impact factor: 4.530

10.  Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret.

Authors:  M D Van Sickle; L D Oland; W Ho; C J Hillard; K Mackie; J S Davison; K A Sharkey
Journal:  Gastroenterology       Date:  2001-10       Impact factor: 22.682

View more
  55 in total

1.  Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review.

Authors:  Justin P Reinert; O'Neill Niyamugabo; Kiersi S Harmon; Norman E Fenn
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

2.  Emerging and Underrecognized Complications of Illicit Drug Use.

Authors:  Alysse G Wurcel; Elisabeth A Merchant; Roger P Clark; David R Stone
Journal:  Clin Infect Dis       Date:  2015-08-12       Impact factor: 9.079

Review 3.  Risks associated with the non-medicinal use of cannabis.

Authors:  Eva Hoch; Udo Bonnet; Rainer Thomasius; Florian Ganzer; Ursula Havemann-Reinecke; Ulrich W Preuss
Journal:  Dtsch Arztebl Int       Date:  2015-04-17       Impact factor: 5.594

Review 4.  Central Aspects of Nausea and Vomiting in GI Disorders.

Authors:  Prashant Singh; Braden Kuo
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

Review 5.  Approach to cannabis use disorder in primary care: focus on youth and other high-risk users.

Authors:  Suzanne D Turner; Sheryl Spithoff; Meldon Kahan
Journal:  Can Fam Physician       Date:  2014-09       Impact factor: 3.275

6.  Cannabinoid hyperemesis syndrome.

Authors:  Chelsey King; Andrew Holmes
Journal:  CMAJ       Date:  2014-09-02       Impact factor: 8.262

7.  A hot mess: a case of hyperemesis.

Authors:  Eileen Cheung; Carly Ng; John Foote
Journal:  Can Fam Physician       Date:  2014-07       Impact factor: 3.275

8.  Hybrids of chemical derivatives of Escherichia coli alkaline phosphatase.

Authors:  E Meighen; R Yue
Journal:  Biochim Biophys Acta       Date:  1975-12-15

9.  Cannabinoid Hyperemesis Syndrome Associated With Compulsive Showering and Acute Kidney Injury.

Authors:  Priya Srihari; Mengyang Liu; Steven Punzell; Shady S Shebak; William S Rea
Journal:  Prim Care Companion CNS Disord       Date:  2016-02-25

Review 10.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.